摘要
胰腺癌的发病率在世界范围内呈逐年上升趋势，其早期诊断困难，手术切除率低，5年生存率仅为5％左右。改善胰腺癌不良预后的关键在于早期诊断和根治性切除。检测血清肿瘤标志物有助于胰腺癌的诊断、预后判断和治疗监测。尽管有一定的局限性，CA19—9仍是目前临床最常用的胰腺癌血清肿瘤标志物。近年来随着分子生物学技术的发展，不断有新的候选胰腺癌血清肿瘤标志物被发掘，如MIC-1、M2-PK、OPN和RCAS1等。本文简要综述了胰腺癌血清肿瘤标志物的研究现状和进展。
The incidence of pancreatic cancer is gradually increasing worldwide. The overall 5-year survival rate of pancreatic cancer is about 5%, because the early diagnosis is difficult and the radical resection rate is low in pancreatic cancer. The keys of improving the poor prognosis of pancreatic cancer are early diag-nosis and radical resection. Detection of serum tumor markers has an important utility in the diagnosis, prognosis and surveillance of pancreatic cancer. CA19-9 is the most widely used and best validated serum tumor marker for pancreatic cancer although it has some limits. With the development of molecular biological tech- nlques in recent yearn, several potential serum tumor markers for pancreatic cancer are undergoing evaluation, including MIC- 1, M2- PK, OPN, RCAS1, and so on. This paper is to review the current status of serum tumor markers of pancreatic cancer.
出处
《国际外科学杂志》
2010年第12期839-843,共5页
International Journal of Surgery
基金
MIC-1血清水平和基因型检测对胰腺癌诊断和预后评估的价值（江西省科技支撑计划项目）
关键词
胰腺癌
血清肿瘤标志物
Pancreatic cancer
Serum tumor marker
